Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

99mTc-based PSMA imaging and surgery agent

A diagnostic radioconjugate composed of a prostate-specific membrane antigen (PSMA)-targeting ligand that is linked, via the bifunctional, macrocyclic chelating agent 1,4,7,10-tetraazacyclododecane-1-(glutamic acid)-4,7,10-triacetic acid (DOTAGA; DOTA-GA), to the radioisotope technetium Tc 99m (Tc99m), that can potentially be used as a radioimaging agent for radio-guided surgery upon single-photon emission computed tomography (SPECT)/computed tomography (CT) for PSMA-overexpressing tumor cells. Upon administration, 99mTc-based PSMA-imaging and surgery (I&S agent targets and binds to PSMA on PSMA-expressing tumor cells. Upon SPECT/CT imaging, PSMA-expressing tumors can be visualized and identified. PSMA, a tumor-associated antigen (TAA), is overexpressed by most prostate cancers.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:99mTc-based PSMA for imaging and surgery
99mTc-DOTAGA-(3-iodo-y)-f-k-Sub(KuE)
99mTc-labeled PSMA-targeting I&S SPECT/CT agent
technetium Tc99m PSMA-targeting agent I&S
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search